Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.52 and traded as high as $0.75. Xtant Medical shares last traded at $0.70, with a volume of 140,912 shares.
Xtant Medical Price Performance
The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88. The firm has a market capitalization of $93.14 million, a price-to-earnings ratio of -5.15 and a beta of 0.35. The business's fifty day simple moving average is $0.55 and its 200 day simple moving average is $0.52.
Institutional Trading of Xtant Medical
A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC lifted its position in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 798,033 shares of the medical device company's stock after purchasing an additional 103,825 shares during the period. Renaissance Technologies LLC owned 0.57% of Xtant Medical worth $354,000 at the end of the most recent quarter. 69.33% of the stock is owned by institutional investors and hedge funds.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Read More
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
